Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
BPI-9016M is a novel, highly potent and selective small-molecule inhibitor of c-Met/Axl
kinase. In preclinical studies, it demonstrated strong activity in vitro and in vivo against
c-Met/Axl kinase and its downstream signaling targets, and inhibited tumor cell growth. This
first-in-human study is conducted to assess the maximum tolerated dose (MTD) and
dose-limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary
anti-tumor activity of BPI-9016M with single doses and multiple doses.